Clinical Trials Browser

Breast Neoplasms, Melanoma

NCT06982521 2026-03-03

ReDiscover-2

Phase 3 Recruiting

540 enrolled

Breast

Breast Neoplasms

NCT07281833 2026-02-27

CAPIcorn

Phase 3 Recruiting

250 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT06635447 2026-01-13

CAPItrue

Phase 3 Recruiting

300 enrolled

Breast

Breast Neoplasms, Disease Progression

NCT06764186 2026-01-13

CAPItana

Phase 3 Active not recruiting

101 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

Phase 3 Active not recruiting

923 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01992952 2025-11-26

FAKTION

Phase 1/2 Active not recruiting

149 enrolled

Breast

Estrogen Receptor Positive Breast Cancer

NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Phase 1 Completed

285 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02423603 2025-03-10

PAKT

Phase 2 Completed

71 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

1,460 enrolled

Breast

Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1 Completed

12 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04712396 2021-04-09

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1 Completed

11 enrolled

BreastGenitourinary

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

NCT03182634 2019-01-22

plasmaMATCH

Phase 2 Unknown

1,150 enrolled

Breast

Advanced Breast Cancer

NCT02077569 2017-05-04

STAKT

Phase 2 Completed

48 enrolled

Breast

Breast Neoplasms

Clinical Trials

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

ReDiscover-2

CAPIcorn

AMTEC IIT: Phase 2 Multiarm Study in TNBC

BEGONIA

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

CAPItrue

CAPItana

ELEVATE

CaptAin

CAPItello-290

DB-08

FAKTION

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

PAKT

SAFIR02_Breast

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

plasmaMATCH

STAKT